Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. Founded in 2014, Compass focuses on developing proprietary antibody-based therapeutics to treat a variety of human diseases, with a strong emphasis on oncology.
The company’s core mission is to thoroughly address the tumor-immune synapse by utilizing combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass industrializes antibody discovery and decentralizes biologic validation through a partnership-first mentality, leveraging best-in-class technologies and top-tier academic laboratories globally. All novel scientific insights are validated extensively within Compass's own labs before proceeding to proprietary combination therapeutics aimed at human clinical trials.
In 2015, Compass secured a $120 million Series A financing to support its ambitious plans to build a fully-integrated biopharmaceutical company. The company’s robust pipeline includes three primary product candidates—CTX-009, CTX-471, and CTX-8371. CTX-009 is a bispecific antibody combining DLL4 and VEGF-A inhibitors, CTX-471 is a CD137 agonist, and CTX-8371 is a PD-1 x PD-L1 bispecific antibody. These candidates are in various stages of clinical development, targeting key pathways in angiogenesis, immune response activation, and immunosuppressive mechanisms within the tumor microenvironment.
Recently, Compass has achieved significant milestones. The company reported top-line data showing promising results in its Phase 2 COMPANION-003 trial and Phase 2/3 COMPANION-002 trial. Additionally, the FDA granted Fast Track Designation to CTX-009 in combination with paclitaxel for metastatic or locally advanced biliary tract cancer. Compass continues to make strides in advancing its product candidates through both standalone therapies and combinations with its proprietary pipeline antibodies.
Financially, Compass maintains a strong position, with a year-end 2023 cash balance of $152 million, extending its cash runway into mid-2026. The company’s net loss for 2023 was $42.5 million, showing a slight increase from the previous year, reflecting its intensified clinical and manufacturing activities.
Looking forward, Compass plans to continue its clinical trials and explore additional therapeutic areas. Key leadership changes and additions, such as the appointment of Vered Bisker-Leib, PhD, as CEO, reflect the company’s commitment to steering towards innovation and growth.
For more detailed and updated information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Compass Therapeutics (CMPX) has appointed Barry Shin as Chief Financial Officer effective December 9, 2024. Shin brings over 20 years of experience in biopharmaceutical leadership, including finance, operations, investment banking, and corporate advisory roles. Most recently, he served as EVP, COO & CFO at Trevena, Inc.
The appointment comes at a important time for Compass, with several key catalysts expected in 2025, including topline data readout for CTX-009 in the first quarter. CEO Thomas Schuetz highlighted Shin's expertise in financial planning, capital markets, and M&A as valuable assets for advancing CTX-009 and the company's portfolio of clinical and pre-clinical assets.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York City. The company's presentation is scheduled for Wednesday, December 4, 2024, from 9:50-10:10 AM EST. A webcast of the presentation will be available and archived for 90 days on Compass' Events page.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in two major healthcare investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference in New York on November 18 at 3:00 PM ET, and at the Jefferies London Healthcare Conference in London on November 21 at 2:00 PM GMT. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.
Compass Therapeutics (NASDAQ: CMPX) reported Q3 2024 financial results and corporate updates. The company fully enrolled its Phase 2/3 trial of CTX-009 in biliary tract cancers, with top-line data expected by Q1 2025. Net loss was $10.5 million ($0.08 per share) for Q3 2024. The company maintains a strong financial position with $135 million in cash and marketable securities, providing runway into Q1 2027. R&D expenses were $8.6 million, while G&A expenses increased to $3.6 million. Key pipeline developments include progress in CTX-471 trials with NCAM identified as a potential response biomarker, and advancement in CTX-8371's Phase 1 dose-escalation study.
Compass Therapeutics presented new biomarker data for CTX-471, their novel anti-CD137 agonist antibody, at the SITC Annual Meeting. The study revealed a significant correlation between neural cell adhesion molecule (NCAM/CD56) expression and patient response to CTX-471 monotherapy. The data comes from a Phase 1 trial in patients with advanced malignancies who previously progressed on PD-1/PD-L1 inhibitors. Key findings showed that tumor cell NCAM appears to enrich activated NK cells in the tumor microenvironment, suggesting NCAM's potential use as a selection marker for future clinical trials.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, announced the acceptance of an abstract for poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The meeting will be held from November 8–10, 2024, in Houston, TX.
The poster presentation, titled 'Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody', will be presented on Friday, November 8, 2024, from 9:00 AM to 7:00 PM CDT in Exhibit Halls AB. The presentation materials will be available on the company's website after the presentation concludes.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, has announced its participation in two major investor events in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 11:00 AM ET in New York. Additionally, Compass will participate in the Cantor Global Healthcare Conference on September 17 at 8:35 AM ET, also in New York.
Both presentations will be available via webcast, with links provided for each event. Investors and interested parties can access the webcasts through the specified URLs. The presentations will be archived for 90 days on Compass Therapeutics' Events page, allowing for extended viewing opportunities. These events provide a platform for Compass to showcase its progress in developing antibody-based therapeutics for oncology applications.
Compass Therapeutics (Nasdaq: CMPX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed enrollment of 150 patients in COMPANION-002 Phase 2/3 trial of CTX-009 for biliary tract cancers (BTC)
- Approved Investigator Sponsored Trial of CTX-009 in first-line BTC setting
- Encouraging preliminary data from COMPANION-003 Phase 2 trial of CTX-009 in colorectal cancer
- Planning Phase 2 monotherapy trial of CTX-471 with newly identified biomarker
- Completed first dosing cohort in Phase 1 study of CTX-8371
Q2 2024 net loss was $13.1 million ($0.10 per share). Cash position of $146 million provides runway into Q1 2027.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer treatments, has announced its participation in the Wedbush PacGrow Healthcare Conference. The event is scheduled for Tuesday, August 13, 2024, at 11 AM ET in New York City.
This conference provides Compass Therapeutics with an opportunity to showcase its progress in developing innovative oncology therapies. As a company dedicated to creating proprietary antibody-based therapeutics for multiple human diseases, Compass's participation in this healthcare conference could offer valuable insights into its current projects and future plans in the biotechnology sector.
Compass Therapeutics (Nasdaq: CMPX) has announced two significant developments in its biliary tract cancer (BTC) program:
1. Completed enrollment of 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel alone in previously treated, unresectable advanced metastatic or recurrent BTC.
2. Approved an Investigator Sponsored Trial (IST) to study CTX-009 in the first-line setting for BTC patients at The University of Texas MD Anderson Cancer Center. This trial will add CTX-009 to the standard first-line regimen of gemcitabine, cisplatin, and durvalumab.
These developments mark significant progress in Compass Therapeutics' oncology-focused antibody-based therapeutics program, potentially expanding treatment options for BTC patients.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
What does Compass Therapeutics, Inc. specialize in?
What are the main product candidates of Compass Therapeutics?
What recent milestones has Compass Therapeutics achieved?
Where is Compass Therapeutics headquartered?
How is Compass Therapeutics financed?
Who are the key executives at Compass Therapeutics?
What is the scientific focus of Compass Therapeutics?
What is the financial condition of Compass Therapeutics?
How does Compass Therapeutics innovate in antibody discovery?
What therapeutic areas is Compass Therapeutics exploring?
